A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemo (Q39037214)
Jump to navigation
Jump to search
scientific article published on 5 January 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemo |
scientific article published on 5 January 2017 |
Statements
A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients (English)
Keitaro Yokoyama
Takashi Shigematsu
Takashi Akiba
Akifumi Fujii
Takuto Kuramoto
Motoi Odani
Tadao Akizawa
ONO-5163 Study Group
1 reference
1 reference
1 reference
1 reference